Reta One-Click Pen

Reta One-Click, also known as Retatrutide, is an investigational triple-receptor agonist designed to activate the GIP, GLP-1 and glucagon receptor pathways. It is currently being studied in Phase 3 clinical trials to assess its safety and efficacy in adults with obesity, overweight and associated health conditions. Retatrutide has not received UK marketing authorisation, and no commercially approved retatrutide pen is currently available. It must not be presented as an approved weight-loss treatment, supplied for self-administration or used outside an appropriately authorised clinical trial.